Dehydroevodiamine attenuates beta-amyloid peptide-induced amnesia in mice

Eur J Pharmacol. 2001 Feb 16;413(2-3):221-5. doi: 10.1016/s0014-2999(00)00913-4.


Dehydroevodiamine has been reported to have anticholinesterase activity and an anti-amnesic effect. This study examined the effects of dehydroevodiamine on scopolamine- and beta-amyloid peptide-(25--35)-induced amnesia in mice, using a step-through passive avoidance test. Similarly to the cholinesterase inhibitor, physostigmine (0.03--0.3 mg/kg, i.p.), dehydroevodiamine (0.75--12.0 mg/kg, i.p.) administered 30 min before the training trial, immediately after the training trial, and 30 min before the retention test significantly improved scopolamine- and beta-amyloid peptide-(25--35)-induced amnesia. In beta-amyloid peptide-(25--35)-induced amnesia, the rank order of anti-amnesic potency in these three administration schedules for dehydroevodiamine was different from that for physostigmine. Furthermore, dehydroevodiamine was more potent to improve beta-amyloid peptide-(25--35)-induced amnesia than scopolamine-induced amnesia when administered before the training trial. These results suggested that dehydroevodiamine may have an action other than that of an anticholinesterase and may be a novel and effective ligand for improvement of beta-amyloid type amnesia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alkaloids / administration & dosage*
  • Alzheimer Disease / drug therapy
  • Amnesia / chemically induced
  • Amnesia / drug therapy*
  • Amyloid beta-Peptides* / adverse effects
  • Animals
  • Avoidance Learning / drug effects*
  • Avoidance Learning / physiology
  • Cholinesterase Inhibitors / administration & dosage*
  • Male
  • Mice
  • Mice, Inbred ICR
  • Muscarinic Antagonists / adverse effects
  • Peptide Fragments* / adverse effects
  • Physostigmine / administration & dosage
  • Scopolamine / adverse effects


  • Alkaloids
  • Amyloid beta-Peptides
  • Cholinesterase Inhibitors
  • Muscarinic Antagonists
  • Peptide Fragments
  • amyloid beta-protein (25-35)
  • dehydroevodiamine
  • Physostigmine
  • Scopolamine